Cargando…

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days a...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Gili, Klein, Elisheva, Lustig, Yaniv, Weiss-Ottolenghi, Yael, Asraf, Keren, Indenbaum, Victoria, Amit, Sharon, Kriger, Or, Gilboa, Mayan, Levy, Yuval, Pessach, Itai M., Kreiss, Yitshak, Regev-Yochay, Gili, Stein, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693260/
https://www.ncbi.nlm.nih.gov/pubmed/36423049
http://dx.doi.org/10.3390/vaccines10111954
_version_ 1784837494473228288
author Joseph, Gili
Klein, Elisheva
Lustig, Yaniv
Weiss-Ottolenghi, Yael
Asraf, Keren
Indenbaum, Victoria
Amit, Sharon
Kriger, Or
Gilboa, Mayan
Levy, Yuval
Pessach, Itai M.
Kreiss, Yitshak
Regev-Yochay, Gili
Stein, Michal
author_facet Joseph, Gili
Klein, Elisheva
Lustig, Yaniv
Weiss-Ottolenghi, Yael
Asraf, Keren
Indenbaum, Victoria
Amit, Sharon
Kriger, Or
Gilboa, Mayan
Levy, Yuval
Pessach, Itai M.
Kreiss, Yitshak
Regev-Yochay, Gili
Stein, Michal
author_sort Joseph, Gili
collection PubMed
description There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days after vaccination for immunogenicity, adverse events, and breakthrough infections. Ninety days after the first vaccine dose, the GeoMean (CI 95%) of IgG ascended to 1291.0 BAU (929.6–1790.2) for uninfected children and 1670.0 BAU (1131.0–2466.0) for Infected children. One hundred and eighty days after receiving the first dose of the vaccine, the titers decreased to 535.5 BAU (288.4–993.6) for the uninfected children, while only a small decline was detected among infected children—1479.0 (878.2–2490.0). The neutralizing antibodies titer almost did not change over time in the uninfected children, and even elevated for the infected children. Of the 110 vaccinated children, 75.5% were infected, with only mild COVID-19 infection symptoms. Child vaccination was found to be safe, with mild, mostly local, and of short duration, reported AEs. No serious adverse events (SAEs) were reported after vaccination. The durability of two doses of vaccine in children is longer, thus a booster may not be needed as early as in adults.
format Online
Article
Text
id pubmed-9693260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96932602022-11-26 Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years Joseph, Gili Klein, Elisheva Lustig, Yaniv Weiss-Ottolenghi, Yael Asraf, Keren Indenbaum, Victoria Amit, Sharon Kriger, Or Gilboa, Mayan Levy, Yuval Pessach, Itai M. Kreiss, Yitshak Regev-Yochay, Gili Stein, Michal Vaccines (Basel) Article There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days after vaccination for immunogenicity, adverse events, and breakthrough infections. Ninety days after the first vaccine dose, the GeoMean (CI 95%) of IgG ascended to 1291.0 BAU (929.6–1790.2) for uninfected children and 1670.0 BAU (1131.0–2466.0) for Infected children. One hundred and eighty days after receiving the first dose of the vaccine, the titers decreased to 535.5 BAU (288.4–993.6) for the uninfected children, while only a small decline was detected among infected children—1479.0 (878.2–2490.0). The neutralizing antibodies titer almost did not change over time in the uninfected children, and even elevated for the infected children. Of the 110 vaccinated children, 75.5% were infected, with only mild COVID-19 infection symptoms. Child vaccination was found to be safe, with mild, mostly local, and of short duration, reported AEs. No serious adverse events (SAEs) were reported after vaccination. The durability of two doses of vaccine in children is longer, thus a booster may not be needed as early as in adults. MDPI 2022-11-18 /pmc/articles/PMC9693260/ /pubmed/36423049 http://dx.doi.org/10.3390/vaccines10111954 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Joseph, Gili
Klein, Elisheva
Lustig, Yaniv
Weiss-Ottolenghi, Yael
Asraf, Keren
Indenbaum, Victoria
Amit, Sharon
Kriger, Or
Gilboa, Mayan
Levy, Yuval
Pessach, Itai M.
Kreiss, Yitshak
Regev-Yochay, Gili
Stein, Michal
Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title_full Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title_fullStr Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title_full_unstemmed Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title_short Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
title_sort real-world immunogenicity and reactogenicity of two doses of pfizer-biontech covid-19 vaccination in children aged 5–11 years
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693260/
https://www.ncbi.nlm.nih.gov/pubmed/36423049
http://dx.doi.org/10.3390/vaccines10111954
work_keys_str_mv AT josephgili realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT kleinelisheva realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT lustigyaniv realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT weissottolenghiyael realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT asrafkeren realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT indenbaumvictoria realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT amitsharon realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT krigeror realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT gilboamayan realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT levyyuval realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT pessachitaim realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT kreissyitshak realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT regevyochaygili realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years
AT steinmichal realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years